SCHEMBL13128957

SCHEMBL13128957

Cc1ccc(N/N=C/c2ccc(CN3CCCCC3)cc2)c(S(=O)(=O)Nc2ccccc2Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.41
▸ MAPT P10636 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ GPR55 Q9Y2T6 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MEN1 O00255 3/20 0.39
▸ KMT2A Q03164 3/20 0.39
▸ PSMD14 O00487 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ PKM P14618 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ PTGES2 Q9H7Z7 1/20 0.38
▸ ALPL P05186 1/20 0.38
▸ ALPI P09923 1/20 0.38
▸ ALPG P10696 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ MAPK1 P28482 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2741014 0.86 MEN1 (0.54) L3MBTL1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2740991 0.80 MAPT (0.56) L3MBTL1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2740950 0.78 MEN1 (0.61) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL13128928 0.77 MEN1 (0.53) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL13128983 0.74 ALDH1A1 (0.43) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL13128959 0.74 KDM4E (0.54) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL2740983 0.72 MEN1 (0.59) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL13128956 0.70 MEN1 (0.48) L3MBTL1MAPTPOLBSMN1; SMN2MEN1
SCHEMBL2740999 0.68 MAPT (0.49) L3MBTL1MAPTPOLBGPR55SMN1; SMN2
SCHEMBL2740948 0.68 L3MBTL1 (0.55) L3MBTL1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT THE GENETICS COMPANY, INC. (CH) 2010-09-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249135-A1 SULFONAMIDES AND THEIR USE AS A MEDICAMENT BCOR, CBR3, SULT1E1 L3MBTL1 1642/4885MAPT 4202/4885POLB 3742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback